Enteroendocrine System and Gut Barrier in Metabolic Disorders

With the continuous rise in the worldwide prevalence of obesity and type 2 diabetes, developing therapies regulating body weight and glycemia has become a matter of great concern. Among the current treatments, evidence now shows that the use of intestinal hormone analogs (e.g., GLP1 analogs and othe...

Descripción completa

Detalles Bibliográficos
Autores principales: Osinski, Céline, Moret, Dounia, Clément, Karine, Serradas, Patricia, Ribeiro, Agnès
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8998765/
https://www.ncbi.nlm.nih.gov/pubmed/35409092
http://dx.doi.org/10.3390/ijms23073732

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8998765/
https://www.ncbi.nlm.nih.gov/pubmed/35409092
http://dx.doi.org/10.3390/ijms23073732

Ejemplares similares